Overall survival of patients with non-small-cell lung cancer
Abstract
Introduction: A lung cancer overall survival rate of 30.1% was estimated in Cuba by age and at five years in the period 2010-2014. This was the worst cancer location analyzed in the country.
Objective: Identify the prognostic factors influencing the overall survival of patients with non-small-cell lung cancer treated at the National Institute of Oncology and Radiobiology from 2010 to 2018.
Methods: A retrospective descriptive study was conducted of all the patients registered for lung cancer (2 189 patients) from 1 January 2010 to 31 December 2018.
Results: Overall survival at five years was estimated at 13% for all the patients with non-small-cell lung cancer, with a median of 8.8 months. Sex, age, histological type, clinical stage at diagnosis and surgical treatment at stage IA, were all variables with a significant influence on overall survival (p < 0.05). The best prognosis was estimated in women, patients aged 65 years or over, a different histological type (carcinoids) and patients diagnosed and treated surgically at stage IA.
Conclusions: Overall survival was low in comparison with the one estimated by similar studies published recently. Only the early diagnosis and timely surgical treatment at stage IA may ensure a significant increase in the overall survival of these patients.
Key words: overall survival; lung cancer.Downloads
References
1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941–953. DOI: https://doi.org/10.1002/ijc.31937
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. DOI: https://doi.org/10.3322/caac.21166
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. DOI: https://doi.org/10.3322/caac.20107
4. De Vita, Hellman and Rosemberg´ Cancer: Principles and practice of Oncology, 8th ed. Cap. 37; 2011. p. 888-939.
5. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100-10. DOI: doi.org/10.1093/carcin/bgp263
6. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765. DOI: https://doi.org/10.1016/j.ejca.2009.12.014
7. Ministerio de Salud Pública. Anuario estadístico de salud, 2019. La Habana: Dirección de Registros Médicos y Estadísticas de Salud. 2020 [acceso]. Disponible en: https://salud.msp.gob.cu
8. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre LA, Jemal A, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. DOI: https://doi.org/10.3322/caac.21492
9. Cheng TYD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME, et al. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. Journal of Thoracic Oncology. 2016;11(10):1653–71. DOI: https://doi.org/10.1016/j.jtho.2016.05.021
10. Jemal A, Miller KD, Ma J. Higher lung cancer incidence in young women than young men in the United States. New England Journal of Medicine. 2018;378(21):1999–2009. DOI: 10.1056/NEJMoa1715907
11. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al., “Global surveillance of trends in cancer survival 2000–2014(CONCORD3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries,” The Lancet. 2018;391(10125):1023–75. DOI: https://doi.org/10.1016/S0140-6736(17)33326-3
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, ET AL. Cancer statistics, 2009. CA Cancer J Clin. 2009;59: 225–49. DOI: https://doi.org/10.3322/caac.20073
13. Horner MJ, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute. 2009 [acceso 15/04/221]. Disponible en: http://seer.cancer.gov/csr/1975_2006/
14. Greene FL, Page DL, Fleming ID, Fritz AG. Cancer Staging Manual. 6th ed. New York, NY: Springer. 2002 [acceso 15/04/221]. Disponible en: https://link.springer.com
15. Morales Sánchez L, Gassiot Nuño C, Nenínger Vinageras E, Prior García A, Rodríguez Vázquez JC. Supervivencia de pacientes con carcinoma broncógeno en el Hospital “Hermanos Ameijeiras” de 1997- 2002. Rev. Cub. Med. 2009 [acceso 15/04/2021];48(3):15-27. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232009000300002
16. Herrera Villalobo C, Rodríguez Vázquez JC, Gassiot Nuño C, Pino Alfonso PP, Cid Guedes A. Influencia de la demora en el diagnóstico y el tratamiento en la supervivencia de pacientes con cáncer pulmonar. Revista Cubana de Medicina. 2007 [acceso 15/04/2021];46(1). Disponible en: https://scielo.sld.cu/scielo.php?pid=S0034-75232007000100008&script=sci_arttext
17. Rodríguez Vázquez JC, Córdoba Alvarado SR, Pino Alfonso PP. La función respiratoria en pacientes con cáncer de pulmón. Revista Cubana Medicina. 2017;56(3). Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232017000300004
18. Martínez Feria F, Matos Pineda LE, Acosta Brooks SC, Cobián Caballero CO. Características clínicas y evolutivas de pacientes con cáncer pulmonar de células pequeñas. MEDISAN. 2016;20(1):42. Disponible en: https://www.medisan.sld.cu/index.php/san/rt/printerFriendly/644/html_207
19. Chiang TA, Chen PH, Wu PF, Wang TN, Chang PY, Ko AMS, et al. Important prognostic factors for the long- term survival of lung cancer subjects in Taiwan. BMC Cancer. 2008;8:324. DOI: https://doi.10.1186/1471-2407-8-324
20. Yue D, Gong L, You J, Su Y, Zhang Z, Zhang Z, et al. Survival analysis of patients with non- small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines. BMC Cancer. 2014 [acceso 15/04/2021];14:422. Disponible en: http://www.biomedcentral.com/1471-2407/14/422
21. Lima Guerra A, Gassiot Nuño C, Ramos Quevedo A, Rodríguez Vázquez JC, Cabanes Varona L, Morales Sánchez L, et al. Conducta diagnóstica y pronóstico en pacientes con carcinoma pulmonar de células no pequeñas en estadios quirúrgicos. Revista Cubana de Medicina. 2012 [acceso 15/04/2021];51(1):15-24. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232012000100003
22. Koodiyedath B, Owen A,Walker J, Suvarna K, Fisher P, Yeomanson D, et al. Non small-cell lung cancer in a 15-year-old nonsmoker. J Thorac Oncol. 2012;7(9):12-3.
23. Halasova E, Adamkov M, Matakova T, Kavkova E, Poliacek I, Singliar A, et al. Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti- apoptotic protein surviving and tumor suppressor P53 protein. Eur J Med Res. 2010;15(SupplII):55-9. DOI: https://doi.org/10.1186/2047-783X-15-S2-55
24. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J. The IASLCC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10:990–1003. DOI: https://doi.org/10.1097/JTO.0000000000000559
25. Lee SE, Kim YJ, Sung M, Lee M-S, Han J, Kim JK, et al. Association with PD-L1 expression and clinic pathological features in 1000 lung cancers: A large single-institution study of surgically resected lung cancers with a high prevalence of EGFR mutation. Int. J. Mol. Sci. 2019;20:4794. DOI:10.3390/ijms20194794
26. Delgado Hernández S, González Ruíz JM. Comorbilidad de pacientes atendidos en la consulta rápida de Cáncer de Pulmón. Universidad de Salamanca. 2016 [acceso 15/04/2021]. Disponible en: https://gredos.usal.es
27. Dutkoswka AE, Antczak A. Comorbidities in lung cancer. Pneumonol Alergol Pol. 2016;84(3):186-92. DOI:10.5603/PiAP.2016.0022.
28. Bossert J, Ludwig M, Wronski P, Koetsenruijter J, Krug K, Villalobos M, et al. Lung cancer patients' comorbidities and attendance of German ambulatory physicians in a 5-years cross- sectional study. NPJ Prim Care Respir Med. 2021;31(1):2. DOI:10.1038/s41533-020-00214-8.
29. Dima S, Chen K-H, Wang K-J, Wang K-M, Teng N-C. Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan. BioMed Research International. 2018;1252897. DOI:10.1155/2018/1252897
30. Leduc C, Antoni D, Charloux A, Falcoz P-E, Quoix E. Comorbidities in the management of patients with lung cancer. Eur Respir J. 2017;49:1601721. DOI: https://doi.org/10.1183/13993003.01721-2016
31. Sigel K, Wisnivesky JP. Comorbidity Profiles of Patients with Lung Cancer: A New Approach to Risk Stratification? Ann Am Thorac Soc. 2017;14(10):1512-3. DOI: 10.1513/AnnalsATS.201706-442ED
32. Seigneurin A, Delafosse P, Trétarre B, Woronoff AS, Velten M, Grosclaude P, et al. Are comorbidities associated with long-term survival of lung cancer? A population- based cohort study from French cancer registries. BMC Cancer. 2018;18:1091. DOI: https://doi.org/10.1186/s12885-018-5000-7
33. Fowler H, Belot A, Ellis L, Maringe C, Luque- Fernández MA, Njeru Njagi E, et al. Comorbidity prevalence among cancer patients: a population- based cohort study of four cancers. BMC Cancer. 2020;20:2. DOI: https://doi.org/10.1186/s12885-019-6472-9
34. Lin H-T, Liu F-C, Wu C-Y, Kuo C-F, Lan W-C, Yu H-P, et al. Epidemiology and survival outcomes of lung cancer: a population- based study. Hindawi BioMed Research International 2019. DOI: https://doi.org/10.1155/2019/8148156
35. Barbosa IR, Bernal Pérez MM, Costa ICC, Jerez-Roig J, de Souza DLB. Supervivencia del cáncer de pulmón en pacientes tratados en un hospital de referencia en Zaragoza. España: Semergen. 2016;42(6):380-7. http://dx.doi.org/10.1016/j.semerg.2015.07.002
36. Roth K, Nilsen TIL, Hatlen E, Sorensen KS, Hole T, Haaverstad R, et al. Predictors of long time survival after lung cancer surgery: A retrospective cohort study. BMC Pulmonary Medicine. 2008 [acceso 15/04/2021];8:22. Disponible en: http://www.biomedcentral.com/1471-2466/8/22
37. Ramírez RA, Beyer DT, Diebold AE, Voros BA, Chester MM, Wang Y-Z, et al. Prognostic factors in typical and atypical pulmonary carcinoids. Ochsner Journal. 2017 [acceso 15/04/2021];17:335–40. Disponible: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718446/#!po=35.0000
38. Cooke DT, Nguyen DV, Yang Y, Chen SL, Yu C, Calhoun RF, et al. Survival comparison of adenosquamous, squamous cell and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg. 2010;90:943-8. DOI: 10.1016/j.athoracsur.2010.05.025
39. Lee J, Park CK, Yoon H-K, Sa YJ, Woo IS, Kim HR, et al. PD-L1 expression in ROS1- rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. Thoracic Cancer. 2019.10:103–110. DOI: 10.1111/1759-7714.12917
40. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, et al. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1≥ 50 % expression in lung adenocarcinoma. J Thorac Oncol. 2016;12(5):878-83. DOI: http://dx.doi.org/10.1016/j.jtho.2016.12.026
41. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non- small cell lung cancer. N Engl J Med. 2020;383(18):1711-23.
42. Ghysen K, Vansteenkiste J. Inmunotherapy in patients with early stage resectable non-small cell lung cancer. Curr Opin Oncol. 2019,31:13–7. DOI:10.1097/CCO.0000000000000497
43. Yang P. Epidemiology of lung cancer prognosis: Quantity and quality of life. Methods Mol Biol. 2009;471:469–86. DOI: http://doi:10.1007/978-1-59745-416-2_24
44. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Patti A. The IASLCC Lungg Cancerr Stagingg Project: Proposals for the Revisions of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007;2(8):706-14. DOI: https://doi.org/10.1097/JTO.0b013e31812f3cla
45. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51. DOI: https://doi.org/10.1016/j.jtho.2015.09.009
46. Wang P, Zhang D, Guo XG, Li XM, Du LH, Sun BJ, et al. A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly. Medicine (Baltimore). 2016;95(52):e5723. DOI:10.1097/MD.0000000000005723
47. Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, et al. Stereotactic body radiation therapy versus surgery for early lung cancer among US veterans. Ann Thorac Surg. 2018;105(2):425–31. DOI: https://doi.org/10.1016/j.athoracsur.2017.07.048
48. Hamaji M, Chen F, Matsuo Y, Kawaguchi A, Morita S, Ueki N, et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. Ann Thorac Surg. 2015 [acceso 15/04/2021];99(4):1122–9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25661580
49. Nakagawa T, Negoro Y, Matsuoka T, Okumura N, Dodo Y. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer. Respir Investig. 2014;52(4):221–6. DOI:10.1016/j.resinv.2014.01.002
50. Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. Eur J Cancer. 2014;50(17):2932–8. DOI: https://doi.org/10.1016/j.ijrobp.2014.05.1847
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
